REVA Medical (RVA) Stock Price, News & Analysis

Company Overview

REVA Medical, Inc., a medical device company, focuses on the development and commercialization of polymer-based bioresorbable products for vascular applications. The company offers Fantom Encore, a bioresorbable vascular scaffold for the treatment of coronary artery disease; and MOTIV bioresorbable vascular scaffold for the treatment of below-the-knee peripheral artery disease. It sells Fantom Encore in Germany, Switzerland, Austria, the Netherlands, Belgium, Luxembourg, Italy, and Turkey. The company was formerly known as MD3, Inc. and changed its name to REVA Medical, Inc. in March 2002. REVA Medical, Inc. was founded in 1998 and is headquartered in San Diego, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RVA Stock Analysis - Frequently Asked Questions

How were REVA Medical's earnings last quarter?

REVA Medical Inc (ASX:RVA) released its quarterly earnings results on Tuesday, August, 7th. The company reported $0.61 earnings per share (EPS) for the quarter.

What other stocks do shareholders of REVA Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that REVA Medical investors own include Enterprise Products Partners (EPD), GrowGeneration (GRWG), Amplify Seymour Cannabis ETF (CNBS), Green Thumb Industries (GTBIF), Arrival (ARVL), Ayr Wellness (AYRWF) and Banxa (BNXA).

Company Calendar

• Last Earnings: 8/07/2018
• Today: 8/07/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: Medical Equipment
• Current Symbol: ASX:RVA
• CIK: N/A
• Web: www.teamreva.com
• Phone: +1-858-9663000
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 414,799,008
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A